宋 国红
北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺肿瘤内科, 恶性肿瘤发病机制及转化研究教育部重点实验室, 北京 100142,
Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education; Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China
李 惠平
北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺肿瘤内科, 恶性肿瘤发病机制及转化研究教育部重点实验室, 北京 100142,
Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education; Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China
邸 立军
北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺肿瘤内科, 恶性肿瘤发病机制及转化研究教育部重点实验室, 北京 100142,
Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education; Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China
严 颖
北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺肿瘤内科, 恶性肿瘤发病机制及转化研究教育部重点实验室, 北京 100142,
Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education; Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China
姜 晗昉
北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺肿瘤内科, 恶性肿瘤发病机制及转化研究教育部重点实验室, 北京 100142,
Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education; Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China
徐 玲
北京大学第一医院乳腺疾病中心, 北京 100034,
Breast Disease Center, Peking University First Hospital, Beijing 100034, China
万 冬桂
中日友好医院中西医结合肿瘤科, 北京 100029,
Department of TCM Oncology, China-Japan Friendship Hospital, Beijing 100029, China
李 瑛
中国人民解放军总医院肿瘤内科,北京 100853,
Department of Oncology, General Hospital of PLA, Beijing 100853, China
王 墨培
北京大学第三医院肿瘤化疗与放射病科, 北京 100191,
Department of Tumor Chemotherapy and Radiation Sickness, Peking University Third Hospital, Beijing 100191, China
肖 宇
北京大学第三医院肿瘤化疗与放射病科, 北京 100191,
Department of Tumor Chemotherapy and Radiation Sickness, Peking University Third Hospital, Beijing 100191, China
张 如艳
北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺肿瘤内科, 恶性肿瘤发病机制及转化研究教育部重点实验室, 北京 100142,
Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education; Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China
冉 然
北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺肿瘤内科, 恶性肿瘤发病机制及转化研究教育部重点实验室, 北京 100142,
Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education; Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China
王 环
北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺肿瘤内科, 恶性肿瘤发病机制及转化研究教育部重点实验室, 北京 100142,
Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education; Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China
北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺肿瘤内科, 恶性肿瘤发病机制及转化研究教育部重点实验室, 北京 100142,
Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education; Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China
北京大学第一医院乳腺疾病中心, 北京 100034,
Breast Disease Center, Peking University First Hospital, Beijing 100034, China
中日友好医院中西医结合肿瘤科, 北京 100029,
Department of TCM Oncology, China-Japan Friendship Hospital, Beijing 100029, China
中国人民解放军总医院肿瘤内科,北京 100853,
Department of Oncology, General Hospital of PLA, Beijing 100853, China
北京大学第三医院肿瘤化疗与放射病科, 北京 100191,
Department of Tumor Chemotherapy and Radiation Sickness, Peking University Third Hospital, Beijing 100191, China
+ metastatic breast cancer
.
Oncologist.
2011;
16
(11):1535–1546.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
9.
Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.
J Clin Oncol.
2010;
28
(1):92–98.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
10.
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
N Engl J Med.
2001;
344
(11):783–792.
[
PubMed
]
[
Google Scholar
]
11.
Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
Cancer.
2007;
110
(5):965–972.
[
PubMed
]
[
Google Scholar
]
12.
Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase Ⅲ study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpres-sing metastatic breast cancer.
J Clin Oncol.
2006;
24
(18):2786–2792.
[
PubMed
]
[
Google Scholar
]
13.
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capeci-tabine for HER2-positive advanced breast cancer.
N Engl J Med.
2006;
355
(26):2733–2743.
[
PubMed
]
[
Google Scholar
]
14.
Cameron D, Casey M, Oliva C, et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase Ⅲ randomized trial.
Oncologist.
2010;
15
(9):924–934.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
15.
Xu BH, Jiang ZF, Chua D, et al. Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Chin J Cancer.
2011;
30
(5):327–335.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
16.
Baselga J, Cortés J, Kim SB. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
N Engl J Med.
2012;
366
(2):109–119.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
17.
Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer.
N Engl J Med.
2012;
367
(19):1783–1791.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
18.
Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
J Clin Oncol.
2009;
27
(31):5278–5286.
[
PubMed
]
[
Google Scholar
]
19.
Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.
J Clin Oncol.
2014;
32
(19):2100–2108.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
20.
Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO clinical practice guideline update.
J Clin Oncol.
2018;
36
(27):2804–2807.
[
PubMed
]
[
Google Scholar
]
21.
Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Lancet Oncol.
2013;
14
(1):64–71.
[
PubMed
]
[
Google Scholar
]
22.
Montemurro F, Ellis P, Delaloge S, et al. Safety and efficacy of trastuzumab emtansine(>T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study.
Cancer Res.
2017;
77
(4 Suppl):P1-12-10.
[
Google Scholar
]
